Global Inhalation Anaesthesia Market Report and Forecast 2024-2032

Global Inhalation Anaesthesia Market Size

The global inhalation anaesthesia market size reached a value of more than USD 1.25 billion in 2023 driven by the increasing prevalence of chronic diseases and medical device manufacturers across the globe. The market is further estimated to grow at a CAGR of 9.40% in the forecast period of 2024-2032.

Global Inhalation Anaesthesia Market Outlook

• The growth of the market is driven by the increasing geriatric population and the rise in the prevalence of chronic diseases requiring surgeries.

• Integration of artificial intelligence and machine learning algorithms in the anesthesia delivery systems is expected to impact the market value positively.

• North America is forecasted to continue to have the largest share of the market due to the increasing incidence of surgeries and well-developed healthcare facilities.

Global Inhalation Anaesthesia Market Overview

Inhalation anaesthesia is a clinical procedure used in medical practice to make patients unconscious or numb during surgery. In this method, anaesthetic agents are delivered as gases or volatile agents to the patient via a face mask, or an endotracheal tube placed in the respiratory tract. Some of these anaesthetic agents include nitrous oxide, sevoflurane, isoflurane, and desflurane. When administered in measured proportions, it provides the ideal level of anaesthesia and pain relief without compromising the body’s basic functions. The sedative agents are transported through the respiratory system, lungs, and circulatory system, affecting the patient’s brain and central nervous system. As the incidence rate of chronic diseases that may require surgeries rise, the demand for inhalational anesthesia is likely to increase in coming years.

Global Inhalation Anaesthesia Market Growth Drivers

Increasing Prevalence of Surgical Procedures Fuels Market Growth

The market for surgical procedures is growing due to the increasing application of inhalation anesthesia in from road accidents and emergencies. Global healthcare faces challenges due to the increasing incidence of diseases such as cancer, respiratory illnesses, and gastrointestinal issues. Chronic diseases like cancer, infectious diseases, and genetic disorders are also rising globally. The American Cancer Society reports that cancer contributes significantly to morbidity and mortality, with an estimated about 1,958,310, new cases and 609,820 cancer-related deaths in 2023. This, coupled with the increasing prevalence of chronic diseases, drives market growth for inhalation anesthesia.

Increased Geriatric Population Promoting the Inhalation Anaesthesia Market

The global geriatric population is expected to drive the growth of inhalation anaesthesia due to their high susceptibility to degenerative and chronic diseases. Elderly patients, particularly those with cardiovascular, neurological, respiratory, or degenerative conditions, are more likely to require surgeries and therapeutics. The discomfort of injecting anaesthesia through intravenous routes for elderly patients is a significant factor, which will continue to influence the consistent demand for inhalation anaesthesia in the coming years.

Global Inhalation Anaesthesia Market Trends

Global Inhalation Anaesthesia Market Segmentation

Market Breakup by Drug Type

• Sevoflurane

• Desflurane

• Isoflurane

• Halothane

Market Breakup by Application

• Induction

• Maintenance

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Inhalation Anaesthesia Market Share

Based on Drug Type Sevoflurane to Hold a Substantial Market Share

Based on drug type, the market is segmented into sevoflurane, desflurane, isoflurane, and halothane. Among these, the increasing use of sevoflurane, owing to several benefits including a pleasant odor, rapid induction, reduced postoperative nausea, and minimal cardiac toxicity are driving its market share. Patients with difficult airways or severe bronchospastic disease are increasingly using sevoflurane due to its reduced irritation to mucous membranes and faster recovery. The drug is also used in both inpatient and outpatient surgeries, and its excellent safety record makes it suitable for both adults and pediatric patients. The increasing approvals of sevoflurane by the Food and Drug Administration (FDA) are expected to further stimulate the market development.

Market Breakup Based on Application Set to Witness Market Growth

The global inhalation anaesthesia market, based on applications is divided into inductive and maintenance. Maintenance anaesthesia is expected to dominate the market because it ensures patients remain unconscious during operations. Maintenance anaesthesia also involves administering anaesthetics in progressively regulated dosages, making it useful for long procedures. This constant demand drives companies to upgrade delivery systems for maintenance, focusing on patient safety and improving technologies for tracking anaesthesia depth and reducing complications.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Inhalation Anaesthesia Market Analysis by Region

The market report reveals regional trends in North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is expected to dominate due to rising surgery rates and hospital requirements. Asia Pacific region is experiencing significant growth due to increasing disease prevalence and the elderly population. Inhalation anaesthetic drugs like Sevoflurane and Desflurane are in high demand due to their fast induction and recovery. The market is estimated to witness revenue growth, especially in response to the growing geriatric population in China.

Leading Players in the Global Inhalation Anaesthesia Market

The key features of the market report include patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:

Halocarbon Life Sciences, LLC.

Established in 1950 and based in Atlanta, Georgia, the key products from this company includes isoflurane USP and Sevoflurane USP, both of which are widely used in human and veterinary medicine. Isoflurane USP is favored for its rapid onset and recovery times, making it a reliable choice for various surgical procedures.

Baxter International Inc.

It is a U.S. based company founded in 1931. This company is a leader in the inhalation anaesthesia market. Their product lineup includes Suprane (Desflurane), Forane (Isoflurane), and Sevoflurane.

AbbVie Inc.

Founded in 2013 and based in North Chicago, Illinois, the company provides Sevoflurane (marketed as Ultane) as its primary inhalation anaesthetic. Ultane is widely used for its quick induction and emergence properties, making it suitable for both pediatric and adult patients.

Sandoz AG

The company was founded in Basel, Switzerland in 1886. The company offers a range of inhalation anaesthetics including Desflurane, Sevoflurane, and Isoflurane. It launched Desflurane as a generic version of Suprane, providing a cost-effective option for maintaining anaesthesia during surgeries.

Other companies include Piramal Enterprises Ltd., Dechra Pharmaceuticals PLC, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, and Troikaa Pharmaceuticals Ltd.

Key Highlights of the Report

Kindly note that this only represents a partial list of companies and the complete list has been in the report.

Key Questions Answered in the Inhalation Anaesthesia Market Report

• What was the global inhalation anaesthesia market value in 2023?
• What is the global inhalation anaesthesia market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is the market segmentation based on drug type?
• What is the market breakup based on application?
• What are the major factors aiding the global inhalation anaesthesia market demand? 
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• What are the major global inhalation anaesthesia market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the inhalation anaesthesia market?
• What are the current unmet needs and challenges?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
• What is the current market size of Sevoflurane in the global inhalation anaesthesia market?
• Who are the leading manufacturers and suppliers of Sevoflurane?
• What regulatory approvals are affecting the market dynamics of Desflurane?
• What are the potential side effects and concerns associated with Desflurane use?
• What are the competitive advantages of Isoflurane over other inhalation anaesthesia?
• How do the induction times of various inhalation anaesthetics compare?
• What percentage of inhalation anaesthetics is used for maintenance during surgeries?
• What are the emerging trends in the maintenance application of the inhalation anaesthesia market?
• What is the current market size and growth rate of inhalation anaesthesia in North America?
• How is the market affected by the healthcare infrastructure in different European countries?
• Which countries in the Asia Pacific are showing the highest demand for inhalation anaesthetics?
• What are the key market drivers and restraints in Latin America?
• How is the healthcare sector evolving in the Middle East and Africa about the inhalation anaesthesia market?